63 related articles for article (PubMed ID: 21884196)
1. Loss of dystroglycan function in oesophageal cancer.
Parberry-Clark C; Bury JP; Cross SS; Winder SJ
Histopathology; 2011 Aug; 59(2):180-7. PubMed ID: 21884196
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis.
Krishnadath KK; Tilanus HW; van Blankenstein M; Hop WC; Kremers ED; Dinjens WN; Bosman FT
J Pathol; 1997 Jul; 182(3):331-8. PubMed ID: 9349237
[TBL] [Abstract][Full Text] [Related]
3. Isolated tumour cells in blood and E-cadherin expression in oesophageal squamous cell cancer.
Setoyama T; Natsugoe S; Okumura H; Matsumoto M; Uchikado Y; Aikou T
Br J Surg; 2007 Aug; 94(8):984-91. PubMed ID: 17410638
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway.
Mariette C; Perrais M; Leteurtre E; Jonckheere N; Hémon B; Pigny P; Batra S; Aubert JP; Triboulet JP; Van Seuningen I
Biochem J; 2004 Feb; 377(Pt 3):701-8. PubMed ID: 14583090
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic beta-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas.
Norwood MG; Bailey N; Nanji M; Gillies RS; Nicholson A; Ubhi S; Darnton JJ; Steyn RS; Womack C; Hughes A; Hemingway D; Harrison R; Waters R; Jankowski JA
Histopathology; 2010 Jul; 57(1):101-11. PubMed ID: 20572881
[TBL] [Abstract][Full Text] [Related]
6. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.
Lin J; Lin L; Thomas DG; Greenson JK; Giordano TJ; Robinson GS; Barve RA; Weishaar FA; Taylor JM; Orringer MB; Beer DG
Clin Cancer Res; 2004 Sep; 10(17):5708-16. PubMed ID: 15355897
[TBL] [Abstract][Full Text] [Related]
7. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.
Sgambato A; De Paola B; Migaldi M; Di Salvatore M; Rettino A; Rossi G; Faraglia B; Boninsegna A; Maiorana A; Cittadini A
J Cell Physiol; 2007 Nov; 213(2):528-39. PubMed ID: 17516554
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation-associated transcriptional silencing of E-cadherin in primary sporadic colorectal carcinomas.
Garinis GA; Menounos PG; Spanakis NE; Papadopoulos K; Karavitis G; Parassi I; Christeli E; Patrinos GP; Manolis EN; Peros G
J Pathol; 2002 Dec; 198(4):442-9. PubMed ID: 12434413
[TBL] [Abstract][Full Text] [Related]
9. Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma.
Corn PG; Heath EI; Heitmiller R; Fogt F; Forastiere AA; Herman JG; Wu TT
Clin Cancer Res; 2001 Sep; 7(9):2765-9. PubMed ID: 11555590
[TBL] [Abstract][Full Text] [Related]
10. Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis.
Liu DS; Hoefnagel SJ; Fisher OM; Krishnadath KK; Montgomery KG; Busuttil RA; Colebatch AJ; Read M; Duong CP; Phillips WA; Clemons NJ
Oncotarget; 2016 Dec; 7(50):83342-83358. PubMed ID: 27863424
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma.
Jiménez P; Piazuelo E; Cebrian C; Ortego J; Strunk M; García-Gonzalez MA; Santander S; Alcedo J; Lanas A
Aliment Pharmacol Ther; 2010 Feb; 31(3):440-51. PubMed ID: 19843025
[TBL] [Abstract][Full Text] [Related]
12. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
Kim CH; Kim J; Kahng H; Choi EC
Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
[TBL] [Abstract][Full Text] [Related]
13. EPLIN-α expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome.
Liu Y; Sanders AJ; Zhang L; Jiang WG
Anticancer Res; 2012 Apr; 32(4):1283-9. PubMed ID: 22493360
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptors may act in a paracrine manner to regulate oesophageal adenocarcinoma growth.
Awan AK; Iftikhar SY; Morris TM; Clarke PA; Grabowska AM; Waraich N; Watson SA
Eur J Surg Oncol; 2007 Jun; 33(5):561-8. PubMed ID: 17254742
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.
Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR
J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.
Tselepis C; Perry I; Dawson C; Hardy R; Darnton SJ; McConkey C; Stuart RC; Wright N; Harrison R; Jankowski JA
Oncogene; 2002 Sep; 21(39):6071-81. PubMed ID: 12203119
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study.
Swami S; Kumble S; Triadafilopoulos G
Am J Gastroenterol; 1995 Oct; 90(10):1808-13. PubMed ID: 7572899
[TBL] [Abstract][Full Text] [Related]
18. N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma.
Yoshinaga K; Inoue H; Utsunomiya T; Sonoda H; Masuda T; Mimori K; Tanaka Y; Mori M
Clin Cancer Res; 2004 Sep; 10(17):5702-7. PubMed ID: 15355896
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Cap43 is associated with malignant status of esophageal cancer.
Sohda M; Mochida Y; Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Fukai Y; Masuda N; Ono M; Kuwano M; Kuwano H
Anticancer Res; 2009 Apr; 29(4):965-70. PubMed ID: 19414333
[TBL] [Abstract][Full Text] [Related]
20. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
